Difference between revisions of "Editorial Board"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
|||
| Line 276: | Line 276: | ||
|Nothing to disclose | |Nothing to disclose | ||
|2021-11-10 | |2021-11-10 | ||
| + | |- | ||
| + | |Brianna Bakow | ||
| + | |Nothing to disclose | ||
| + | |Nothing to disclose | ||
| + | |2022-11-30 | ||
|- | |- | ||
|Danielle S. Bitterman | |Danielle S. Bitterman | ||
| Line 435: | Line 440: | ||
|Nothing to disclose | |Nothing to disclose | ||
|Ownership: HemOnc.org<br> Stock: Merck, Pfizer | |Ownership: HemOnc.org<br> Stock: Merck, Pfizer | ||
| − | |2022- | + | |2022-11-30 |
|- | |- | ||
|Marjorie Zauderer | |Marjorie Zauderer | ||
Revision as of 10:27, 30 November 2022
Our editorial board is comprised of cancer experts, organized primarily by disease focus. Most disease types now have expert representation, but we are still looking for potential section or page editors. If you are interested, please feel free to contact us with any questions or inquiries, at [email protected].
Editor-in-Chief
 |
Peter C. Yang, MD Boston, MA  Hem_Onc
|
Dr. Yang is board certified in Hematology and Medical Oncology; he practices at an academically affiliated institution in Massachusetts. |
Deputy Editor
 |
Jeremy L. Warner, MD, MS, FAMIA, FASCO Brown University Providence, RI |
Dr. Warner is board certified in Hematology, Medical Oncology, and Clinical Informatics; he practices at the Lifespan Cancer Institute. He is an Associate Professor (appointment pending) of Medicine and Public Health at Brown University. He is the Director of the Brown/Lifespan Center for Cancer Bioinformatics and Data Science. |
Associate Editors
| Evidence-based Oncology | ||
|---|---|---|
 |
Bishal Gyawali, MD, PhD Queen’s University Kingston, Canada oncology_bg
|
Dr. Gyawali is an Associate Professor in the Departments of Oncology and Public Health Sciences at Queen’s University, Kingston, Canada and an Ontario Institute for Clinical Research-Scientist II. He is an advocate of a "cancer groundshot", a term he coined to imply that investment should be made on proven high-value interventions in cancer care that are easy to implement globally and are affordable. |
| Cancer Registries | ||
 |
Mary Mesnard, BS, CTR |
Ms. Mesnard is a senior study director at Westat and was formerly with the State of Maryland's central cancer registry. |
| Pediatric Hematology/Oncology | ||
 |
Wayne H. Liang, MD, MS, FAMIA Emory University Atlanta, GA WayneLiangMD |
Dr. Liang is board certified in Pediatrics, Pediatric Hematology-Oncology, and Clinical Informatics; he practices at Children’s Healthcare of Atlanta. He is an Assistant Professor of Pediatrics at Emory University. |
| Radiation Oncology | ||
 |
Danielle S. Bitterman, MD Dana-Farber Cancer Institute Boston, MA |
Dr. Bitterman is board certified in Radiation Oncology; she practices at Brigham and Women’s Hospital/Dana-Farber Cancer Institute. She is an Instructor of Radiation Oncology at Harvard Medical School. |
| Supportive Oncology | ||
 |
Maryam B. Lustberg, MD, MPH Yale University New Haven, CT |
Dr. Lustberg is board certified in Medicine and Medical Oncology; she is the director of the Breast Center at Smilow Cancer Hospital and chief of Breast Medical Oncology at Yale Cancer Center. She is an Associate Professor of Internal Medicine (Medical Oncology) at Yale University. She is the co-chair of Symptom Intervention Committee for Alliance Clinical Trials, and the 2022 president of the Multinational Association of Cancer Supportive Care (MASCC) |
Section Editors
| Breast Oncology | ||
|---|---|---|
 |
H. Deepika Fernandes, MD, FACP Tempe, AZ |
Dr. Fernandes is board certified in Medical Oncology and Hematology; she practices at the HonorHealth Virginia G. Piper Cancer Care Network. |
| Dermatologic Oncology | ||
 |
Elizabeth Buchbinder, MD Boston, MA |
Dr. Buchbinder is board certified in Medical Oncology; she is a senior physician at the Dana-Farber Cancer Institute. She is an Assistant Professor of Medicine at Harvard Medical School. |
| Endocrine Oncology | ||
| Unfilled | If you are interested in this role, please contact us at [email protected]. | |
| Gastrointestinal Oncology, Intestinal | ||
| Unfilled | If you are interested in this role, please contact us at [email protected]. | |
| Gastrointestinal Oncology, Extraintestinal | ||
 |
Eric I. Marks, MD Boston, MA |
Dr. Marks is board certified in Medical Oncology; he practices at Boston Medical Center and is an Assistant Professor of Medicine at Boston University School of Medicine. |
| Genitourinary Oncology | ||
 |
Ali Raza Khaki, MD Palo Alto, CA |
Dr. Khaki is board certified in Hematology and Medical Oncology; he practices at Stanford Health Care. He is a a Clinical Assistant Professor of Oncology at Stanford University School of Medicine. |
| Gynecologic Oncology | ||
 |
Alaina J. Brown, MD, MPH Nashville, TN |
Dr. Brown is board certified in Gynecologic Oncology and Obstetrics and Gynecology; she practices at the Vanderbilt-Ingram Cancer Center. She is an Assistant Professor of Obstetrics and Gynecology at Vanderbilt University. |
| Head & Neck Cancer | ||
 |
Michael K. Gibson, MD, PhD, FACP Nashville, TN mgibson21212 |
Dr. Gibson is board certified in Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center, where he is the Director of Translational Research for Head and Neck Oncology. He is an Associate Professor of Medicine at Vanderbilt University. |
| Mesothelioma | ||
 |
Marjorie G. Zauderer, MD New York, NY MGZauderer
|
Dr. Zauderer is board certified in Medical Oncology; she is co-director of the mesothelioma program at Memorial Sloan Kettering Cancer Center. |
| Neuro-Oncology | ||
 |
Seema Nagpal, MD Palo Alto, CA |
Dr. Nagpal is board certified in Neurology and UCNS certified in Neuro-Oncology; she practices at Stanford Health Care. She is a clinical associate professor at Stanford University |
| Sarcoma | ||
 |
Elizabeth J. Davis, MD Nashville, TN ejdavis25
|
Dr. Davis is board certified in Medical Oncology; she practices at the Vanderbilt-Ingram Cancer Center and is the medical director of the Clinical Trials Office. She is an associate professor at Vanderbilt University. |
| Thoracic Oncology | ||
 |
Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN AmitKulkarniMD
|
Dr. Kulkarni is board certified in Medical Oncology; he practices and is an Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation at the University of Minnesota. |
| Acute Leukemias | ||
 |
Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO |
Dr. Schoen is board certified in Hematology and Medical Oncology; he practices at the Saint Louis Veterans Affairs Medical Center. He is an assistant professor at Saint Louis University. |
| Myeloproliferative Neoplasms and Myelodysplastic Syndromes | ||
 |
Sanjay R. Mohan, MD, MSCI Nashville, TN |
Dr. Mohan is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University. |
| Aggressive Lymphomas & Lymphoproliferative disorders | ||
 |
Tarsheen K. Sethi, MD, MSCI Yale University New Haven, CT tarsheen2
|
Dr. Sethi is board certified in Hematology and Medical Oncology; she practices at the Smilow Cancer Hospital at Yale New Haven. She is an assistant professor at Yale University. |
| Indolent Lymphomas | ||
 |
Sanjai Sharma, MD Visalia, CA |
Dr. Sharma is board certified in Hematology and Medical Oncology; he practices at the Sequoia Regional Cancer Center. |
| Plasma Cell Dyscrasias | ||
 |
Andrew J. Cowan, MD Seattle, WA andrewcowanmd |
Dr. Cowan is board certified in Hematology and Medical Oncology; he is the Interim Clinical Director of the myeloma service at the Fred Hutch Cancer Center. He is an assistant professor at the University of Washington. |
| T-cell and NK-cell neoplasms | ||
 |
Bhagirathbhai Dholaria, MBBS Nashville, TN |
Dr. Dholaria is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University. |
| Histiocyte Disorders | ||
 |
Gaurav Goyal, MBBS UAB Birmingham, AL GauravGoyalMD
|
Dr. Goyal is board certified in Hematology and Medical Oncology; he practices at the O'Neal Comprehensive Cancer Center at UAB Medicine. He is an assistant professor at UAB (The University of Alabama at Birmingham). |
| Pediatric Leukemia & Lymphoma | ||
 |
David Noyd, MD, MPH University of Oklahoma Oklahoma City, OK |
Dr. Noyd is board certified in Pediatrics and board eligible in Pediatric Hematology-Oncology; he practices at OU Health. He is an Assistant Professor of Pediatrics. |
| Pediatric Neuro-Oncology & Solid Tumors | ||
 |
Nikki M. Wood, DO University of Missouri Kansas City, MO WoodNikkiM |
Dr. Wood is board certified in Pediatrics and Pediatric Hematology-Oncology; she practices at Children's Mercy Kansas City. She is an Assistant Professor of Pediatrics. |
| Transplant | ||
 |
Talal Hilal, MD Mayo Clinic Phoenix, AZ THilalMD
|
Dr. Hilal is board certified in Hematology and Medical Oncology; he practices at Mayo Clinic Arizona. He is an assistant professor at the Mayo Clinic. |
| Classical Hematology | ||
 |
Benjamin Tillman, MD Vanderbilt University Nashville, TN |
Dr. Tillman is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an Assistant Professor of Medicine (Hematology/Oncology) |
| Clinical Pharmacology | ||
 |
Austin Fitts, PharmD Vanderbilt University Nashville, TN |
Dr. Fitts is a PGY2 Pharmacy Informatics Resident at Vanderbilt University Medical Center. |
| Living Systematic Reviews | ||
 |
Irbaz Bin Riaz, MD, PhD, MS Mayo Clinic Phoenix, AZ |
Dr. Riaz is board certified in Internal Medicine and board eligible in Medical Oncology; he is currently a Mayo Clinic Scholar training in clinical informatics at the Harvard Medical School Clinical Informatics Program. |
Page Editors
- Jon Arnason, MD (Beth Israel Deaconess Medical Center, Boston, MA)
- Brianna Bakow, MD (Lifespan/Brown University, Providence, RI)
- Karine A. Darbinyan, MD (Altru Cancer Center, Grand Forks, ND)
- Teja Ganta, MD (Icahn School of Medicine at Mount Sinai, Manhattan, NY)
- Laura S. Graham, MD (University of Colorado, Anschutz Medical Campus, Aurora, CO)
- Matthew Hadfield, DO (Lifespan/Brown University, Providence, RI)
- Ashwin Kishtagari, MD (Vanderbilt University, Nashville, TN)
- Shalin Kothari, MD (Yale University, New Haven, CT)
- Mary L. Kwok, MD, FACP (Fred Hutch Cancer Center, Seattle, WA)
- Eric I. Marks, MD (Boston University, Boston, MA)
- Francesca Montanari, MD (Yale University, New Haven, CT)
- Ryan H. Nguyen, DO (University of Illinois at Chicago, IL)
- Samuel M. Rubinstein, MD (University of North Carolina, Chapel Hill, NC)
- Eric K. Singhi, MD (MD Anderson Cancer Center, Houston, TX)
- Risa L. Wong, MD (UPMC, Pittsburgh, PA)
- Leyre Zubiri, MD, PhD (Massachusetts General Hospital, Boston, MA)
COI Disclosures
Please see our conflict of interest page for more details. Disclosures here are for COI within 12 months of the date of disclosure unless otherwise noted.
| Name | Research funding (to institution) | Other (honoraria, travel support, significant ownership interests, etc.) | Date of disclosure |
|---|---|---|---|
| Jon Arnason | Nothing to disclose | Nothing to disclose | 2021-11-10 |
| Brianna Bakow | Nothing to disclose | Nothing to disclose | 2022-11-30 |
| Danielle S. Bitterman | Nothing to disclose | Nothing to disclose | 2022-11-10 |
| Alaina J. Brown | NIH | Nothing to disclose | 2022-08-03 |
| Elizabeth Buchbinder | NIH; Trial funding: Eli Lilly, Novartis, Partners therapeutics, Genentech, BVD | Consulting/Advisory Board: Novartis, Apexigen, Shionogi, BMS, Instilbio, Nektar | 2022-05-08 |
| Andrew Cowan | Abbvie, Nektar, Harpoon, Janssen, Adaptive, Sanofi, BMS, Celgene | Consultancy: Abbvie, BMS, Secura Bio, EUSA, GSK | 2022-04-26 |
| Karine A. Darbinyan | Nothing to disclose | Nothing to disclose | 2022-08-03 |
| Elizabeth J. Davis | Research funding: NIH/NCI; ECOG Trial funding: Karyopharm, BMS, Incyte, Actuate, Bio Atla, Top Alliance Biosciences, Genentech |
Consulting/Advisory Board: Deciphera | 2021-11-10 |
| Bhagirathbhai Dholaria | Research funding: Janssen, Angiocrine, Pfizer, Poseida, MEI, Orcabio, Wugen, Allovir | Consulting/Advisory Board: Jazz, Gamida Cell, MJH BioScience, Arivan Research, BEAM therapeutics, Janssen, Atheneum; Study steering committee: Gamida Cell | 2022-08-04 |
| H. Deepika Fernandes | Nothing to disclose | Nothing to disclose | 2021-04-03 |
| Teja Ganta | Nothing to disclose | Nothing to disclose | 2022-08-05 |
| Michael K. Gibson | Nothing to disclose | Nothing to disclose | 2021-11-15 |
| Gaurav Goyal | Nothing to disclose | Royalties from UpToDate and consulting fees from 2nd.MD | 2022-08-02 |
| Laura Graham | Nothing to disclose | Nothing to disclose | 2022-08-04 |
| Bishal Gyawali | Nothing to disclose | Consulting/Advisory Board: Vivio Health | 2022-08-24 |
| Talal Hilal | Nothing to disclose | Consulting/Advisory Board: Incyte Editorship: Springer |
2022-08-22 |
| Ali R. Khaki | Nothing to disclose | Consulting/Advisory Board: Seagen/Astellas Travel: BCAN; SABCS Honoraria: Onclive CME |
2021-11-11 |
| Ashwin Kishtagari | Nothing to disclose | Consulting/Advisory Board: CTI BioPharma | 2022-08-03 |
| Mary L. Kwok | Nothing to disclose | Nothing to disclose | 2022-04-21 |
| Wayne H. Liang | Nothing to disclose | Consulting/Advisory Board: Westat | 2021-11-10 |
| Eric Marks | Nothing to disclose | Nothing to disclose | 2022-04-25 |
| Sanjay R. Mohan | Trial funding: Incyte, Karyopharm, Novartis, Taiho | Nothing to disclose | 2022-04-22 |
| Seema Nagpal | Trial funding: Agios, PharmAbcine, Insightec, Berg, Inovio | Consulting/Advisory Board: EnClear, SeaGen, Novocure Steering Committee, Nurix, Biocept Steering Committee; Guidelines: NCCN CNS committee, ARS-AUC CNS committee, ASTRO Brain metastases guideline committee | 2022-04-22 |
| Ryan Nguyen | Nothing to disclose | Nothing to disclose | 2022-08-04 |
| David Noyd | Nothing to disclose | Nothing to disclose | 2022-08-31 |
| Samuel R. Rubinstein | Nothing to disclose | Consulting/Advisory Board: Sanofi, Roche, Janssen, EUSA pharma | 2022-08-03 |
| Martin Schoen | St. Louis Veterans Affairs Medical Center, Congressionally Directed Medical Research Program | Consulting/Advisory Board: Doximity, Pfizer | 2022-08-05 |
| Sanjai Sharma | Nothing to disclose | Nothing to disclose | 2022-08-04 |
| Eric K. Singhi | Nothing to disclose | Nothing to disclose | 2022-08-02 |
| Benjamin F. Tillman | Nothing to disclose | Nothing to disclose | 2021-10-13 |
| Jeremy L. Warner | AACR; NIH; Vanderbilt University | Travel: AACR; ASCO Ownership: HemOnc.org Consulting/Advisory Board: Westat, MelaxTech, Roche, Flatiron Health; Editorship: ASCO |
2022-05-08 |
| Risa L. Wong | Nothing to disclose | Consulting/Advisory Board: Voluntis | 2022-08-03 |
| Nikki M. Wood | Nothing to disclose | Consulting/Advisory Board: Westat | 2021-11-10 |
| Peter C. Yang | Nothing to disclose | Ownership: HemOnc.org Stock: Merck, Pfizer |
2022-11-30 |
| Marjorie Zauderer | Memorial Sloan Kettering receives research funding from the Department of Defense, the National Institutes of Health, Precog, GlaxoSmithKline, Epizyme, Polaris, Sellas Life Sciences, Bristol Myers Squibb, Millenium/Takeda, Curis, and Atara for research conducted by Dr. Zauderer. | In the last 3 years, Dr. Zauderer has received consulting fees from Curis, Ikena, Takeda, GlaxoSmithKline, Aldeyra Therapeutics, Novocure, and Atara and honoraria for CME content from PER, Medscape, Research to Practice, Medical Learning Institute and OncLive. Dr. Zauderer serves as Chair of the Board of Directors of the Mesothelioma Applied Research Foundation, uncompensated. | 2022-10-20 |